Skip to content

Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.

Featured In Oncology

The PARADIGM study compared intensive induction chemotherapy (IC) to a novel combination therapy, azacitidine and venetoclax (aza-ven), in patients newly diagnosed with acute myeloid leukemia and eligible for IC. Results showed that aza-ven clearly outperformed IC in patients enrolled on study.

Featured In Cardiovascular

Gregory D. Lewis, MD, and colleagues recommend measuring time to VO2 recovery of 12.5% after cardiopulmonary exercise testing of patients with dyspnea on exertion, showing that this metric closely reflects cardiac-specific performance and predicts heart failure outcomes.

Featured In Otolaryngology

A study comparing gene therapy and cochlear implants found comparable or improved outcomes, while new research in mouse models highlights potential treatments for late-onset genetic deafness.

Featured In Endocrinology

Massachusetts General Hospital research indicates that more Americans have obesity based on new obesity classification that uses BMI and anthropometric measurements.

Featured In Orthopaedics

Orhun Muratoglu, PhD, Ebru Oral, PhD, and their team are developing a gentamicin-containing polyethylene material to deliver localized antibiotics for total joint replacements. Their goal is to reduce periprosthetic joint infections and improve the outcomes of two-stage revision surgeries, the current standard of care.

The Latest Oncology Advances

New research with roots at Mass General Brigham Cancer Institute shows that combining age-adjusted PSA thresholds with upfront MRI improves detection of clinically significant prostate cancer in genetically high-risk men—outperforming either test alone.

After being diagnosed with an ameloblastoma in his right mandible at age 20, a patient had numerous surgical debulking and reconstructive procedures. When further surgery was no longer possible, he enrolled in a first-in-human trial of a drug that targets the Wnt/β-catenin pathway. The drug produced a dramatic radiographic response, including near resolution of several tumor masses and reduction in pressure on the brain.

Contributing Physicians

Vice Chair of Research, Department of Surgery, Massachusetts General Hospital, Section Head, Melanoma and Sarcoma Surgery Programs, Surgical Director, Termeer Center for Targeted Therapies, Mass General Brigham Cancer Institute

Director, Cellular Immunotherapy Program, Mass General Brigham Cancer Institute, Associate Professor of Medicine, Harvard Medical School

Marcela Maus, MD, PhD, Profile Image

Advances Specialties

Neuroscience

Two Mass General Brigham neurologists spent nearly a year examining how five esteemed academic health systems are using population health approaches to improve neurologic care. They are among the authors of a paper summarizing relevant case studies and lessons learned from their investigation.

Orthopaedics

Could a minimally invasive procedure ease chronic musculoskeletal pain? Yan Epelboym, MD, MPH, discusses the promise of trans-arterial embolization.

Education & Training Opportunities

May 9, 2025

The Midlife Women's Health 2025 course is led by a multidisciplinary group of experts from Massachusetts General Hospital who will present on the evaluation and management of osteoporosis, gastrointestinal malignancy, stress, obesity, substance use disorder, anxiety, sexual dysfunction, breast cancer, and menopausal hormone therapy to assist clinicians in caring for their midlife patients.

Clinical Trials

In Neuroscience

The study involves multiple visits over 6 months. You will complete an 8-week stress reduction treatment that includes a medical device worn in the ear and attend MRI and PET scans. You will also complete daily migraine diaries online.

In Cardiovascular

The purpose of this research study is to learn about the effects of stress on the brain and disease of the heart and blood vessels (cardiovascular disease or CVD).